P

Protalix BioTherapeutics

PLX

1.06000
USD
-0.02
(-1.85%)
مفتوح الان
حجم التداول
5,913
الربح لكل سهم
0
العائد الربحي
0
P/E
-4
حجم السوق
75,748,954
أصول ذات صلة
P
PAVM
-0.06460
(-7.43%)
0.80530 USD
P
PHX
-0.01000
(-0.31%)
3.26000 USD
P
PLXP
-0.00370
(-2.62%)
0.13000 USD
P
PLXS
-3.840
(-2.99%)
124.500 USD
P
PULM
0.19000
(8.72%)
2.37000 USD
P
PX
-0.31200
(-3.13%)
9.64800 USD
P
PXD
0
(0%)
0.000000 USD
P
PXLW
-0.04310
(-4.39%)
0.93840 USD
الأخبار المقالات

العنوان: Protalix BioTherapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.